Ribavirin Can Be Mutagenic for Arenaviruses
- 15 July 2011
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 85 (14) , 7246-7255
Abstract
Arenaviruses include several important human pathogens, and there are very limited options of preventive or therapeutic interventions to combat these viruses. An off-label use of the purine nucleoside analogue ribavirin (1-β-d-ribofuranosyl-1-H-1,2,4-triazole-3-carboxamide) is the only antiviral treatment currently available for arenavirus infections. However, the ribavirin antiviral mechanism action against arenaviruses remains unknown. Here we document that ribavirin is mutagenic for the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV) in cell culture. The mutagenic activity of ribavirin on LCMV was observed under single- and multiple-passage regimes and could not be accounted for by a decrease of the intracellular GTP pool promoted by ribavirin-mediated inhibition of inosine monophosphate dehydrogenase (IMPDH). Our findings suggest that the antiviral activity of ribavirin on arenaviruses might be exerted, at least partially, by lethal mutagenesis. Implications for antiarenavirus therapy are discussed.Keywords
This publication has 98 references indexed in Scilit:
- T-705 (Favipiravir) Inhibition of Arenavirus Replication in Cell CultureAntimicrobial Agents and Chemotherapy, 2011
- Lethal Mutagenesis: Targeting the Mutator Phenotype in CancerSeminars in Cancer Biology, 2010
- Structure of Foot-and-Mouth Disease Virus Mutant Polymerases with Reduced Sensitivity to RibavirinJournal of Virology, 2010
- Effect of Ribavirin on the Mutation Rate and Spectrum of Hepatitis C Virus In VivoJournal of Virology, 2009
- Determinants of RNA-Dependent RNA Polymerase (In)fidelity Revealed by Kinetic Analysis of the Polymerase Encoded by a Foot-and-Mouth Disease Virus Mutant with Reduced Sensitivity to RibavirinJournal of Virology, 2008
- Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patientsHepatology, 2008
- Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment–Naïve Populations and Associate with Reduced Treatment EfficacyPLOS Medicine, 2008
- Inhibition of cellular entry of lymphocytic choriomeningitis virus by amphipathic DNA polymersVirology, 2008
- Analysis of Ribavirin Mutagenicity in Human Hepatitis C Virus InfectionJournal of Virology, 2007
- Foot-and-Mouth Disease Virus Mutant with Decreased Sensitivity to Ribavirin: Implications for Error CatastropheJournal of Virology, 2007